Kenneth Alan Iczkowski

Dr. Kenneth Alan Iczkowski


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YMYuki Murakami
Yuki Murakami
KLKamhung Lam
Kamhung Lam
SFShinsuke Fukui
Shinsuke Fukui
EHElizabeth Helmke
Elizabeth Helmke
KIKenneth Alan Iczkowski
Kenneth Alan Iczkowski
NSNoriko Satake
Noriko Satake
Background: Rhabdoid tumor of the kidney (RTK) is a highly aggressive pediatric malignancy characterized by biallelic SMARCB1 loss, resulting in aberrant MYC pathway activation and cell cycle regulation. MYC-activated tumors are vulnerable in splicing functions and sensitive to splicing inhibitors. Therefore, in this study, cyclin-dependent kinase 11 (CDK11), which regulates both cell cycle and RNA splicing, was tested as a therapeutic target in RTK. Methods: CDK11A/B expression was analyzed using the TARGET-RT database. The therapeutic efficacy of the CDK11 inhibitor OTS964 was evaluated in two RTK cell lines (G401 and JMU-RTK-2) and a JMU-RTK-2 xenograft mouse model. Cytotoxicity, apoptosis, cell cycle, and RNA splicing were examined using the Sulforhodamine B assay, immunoblotting, flow cytometry, and RT-PCR. Results: CDK11B, but not CDK11A, was significantly upregulated in RTK and correlated with the poor survival. OTS964 inhibited RTK cell growth in vitro with the IC50 of 33.1 nM (G401) and 19.3 nM (JMU-RTK-2) and significantly prolonged survival in vivo (median survival: 46.5 vs. 37.0 days, p < 0.01) without marked toxicity. Mechanistically, OTS964 induced G2/M cell cycle arrest and p53 upregulation, disrupted RNA splicing via SF3B1 dephosphorylation, and ultimately led to apoptosis through caspase-3 activation. Conclusions: CDK11 inhibition by OTS964 effectively suppresses RTK growth through cell cycle arrest and RNA splicing inhibition, leading to apoptosis. OTS964 shows potent anti-tumor activity and tolerability, supporting CDK11 as a promising therapeutic target for RTK and related SMARCB1-deficient cancers.

1 March 2026 in Journal of Biomedical Optics
Verified
Journal Article
Open access
JBJulien Bec
Julien Bec
XZXiangnan Zhou
Xiangnan Zhou
YTYash Tipirneni
Yash Tipirneni
SCShuai Chen
Shuai Chen
JQJinyi Qi
Jinyi Qi
LMLaura Marcu
Laura Marcu
SignificanceProstate biopsy remains the gold standard for prostate cancer (PCa) diagnosis and treatment planning. However, current techniques suffer from low cancer detection rates, with most biopsy cores sampling benign tissue, leading to undergrading and repeat procedures. Label-free fluorescence lifetime imaging (FLIm) offers a potential solution by enabling real-time discrimination between malignant and benign tissue during biopsy collection, potentially reducing both the number of cores required and the repeat biopsy rates.AimThis pilot study evaluates the feasibility of label-free FLIm for rapid discrimination of malignant from benign prostate tissue in freshly obtained core needle biopsies.ApproachTwenty patients undergoing prostate biopsy were enrolled. FLIm measurements were performed immediately after sample collection (∼10 s) using a custom fiber-optic probe. For each point measurement, FLIm parameters from four spectral bands associated with the emission of distinct endogenous fluorophores including structural proteins and metabolic cofactors (e.g., NADH and FAD) were entered in the analysis. Each FLIm point measurement was labeled based on histological annotation. These data were analyzed to characterize tissue-type differences and to train and evaluate support vector machine (SVM) classifiers for malignancy detection.ResultsSeparation between benign tissue and Gleason pattern ≥4 PCa can already be observed using just 2 out of 56 FLIm-derived parameters. The SVM classifier, using all parameters, achieved a receiver operating characteristic of 0.88 for identifying Gleason pattern 4 PCa. A shorter lifetime value observed in the NADH-associated band was observed for Gleason pattern 4 PCa relative to benign tissue, consistent with increased free NADH from upregulated glycolysis, supporting the biochemical basis for optical differentiation.ConclusionsFLIm demonstrates strong potential for identifying high-grade PCa. Because measurements were performed using a single fiber optic, this approach can be readily integrated into standard prostate biopsy devices to enable FLIm-guided and real-time tissue characterization during the biopsy procedure and to inform targeted tissue collection.

Verified
Journal Article
Open access
PDF file
HQHuan Qu
Huan Qu
PXPengfei Xu
Pengfei Xu
JYJoy C. Yang
Joy C. Yang
FWFan Wei
Fan Wei
JZJunwei Zhao
Junwei Zhao
CLChengfei Liu
Chengfei Liu
Treatment-induced neuroendocrine prostate cancer (t-NEPC) is the major form of resistance to androgen receptor signaling inhibitors (ARSI) in advanced prostate cancer, characterized by pronounced invasiveness and lineage plasticity. Through in-depth analysis of prostate cancer cohorts, we found that glutamate ionotropic receptor kainate (GRIK) family members, specifically GRIK2 and GRIK5, are highly expressed in neural lineage plastic prostate cancer cells, NEPC patient-derived xenografts (PDX), and NEPC patient samples. Their expression positively correlates with neuroendocrine markers and inversely correlates with androgen receptor (AR) activity. Additionally, functional analyses indicated that AR has a direct transcriptional inhibitory effect on GRIK2 and GRIK5, and the absence of AR signaling leads to the upregulation of GRIK2 and GRIK5. Further RNA sequencing analysis revealed that GRIK5 silencing reprograms the cellular transcriptome, resulting in significant downregulation of AR signaling and fatty acid metabolism, while simultaneously activating immune and inflammatory responses in enzalutamide-resistant prostate cancer cells. In both cell line and NEPC PDX organoid models, loss of GRIK5 impaired proliferation and clonogenic growth. Notably, GRIK5 also contributes to enzalutamide resistance. Pharmacological evaluation revealed that Pan-GRIK antagonists exhibit anti-tumor activity, although the required relatively high concentrations suggest that more potent therapeutic strategies should be developed. Collectively, this study establishes that GRIK family members play critical roles in enzalutamide resistance and NEPC progression, highlighting GRIK signaling as a potential therapeutic target for overcoming lineage plasticity in prostate cancer.